Lead researcher Jin Hokyung said, "Our study identified the nasopharyngeal lymphatic plexus as a hub for CSF outflow. CSF ...

Considering taking supplements to treat nasopharyngeal cancer? Below is a list of common natural remedies used to treat or reduce the symptoms of nasopharyngeal cancer. Follow the links to read ...

in India under the brand name Zytorvi for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC), a rare form of head and neck cancer. Loqtorzi, a novel anti-PD-1 ...

Researchers from Taiwan have recently published the results of a study on preradiotherapy imaging for nasopharyngeal carcinoma (NPC). To the authors' knowledge, this is the first study of this ...

(RTTNews) - Dr. Reddy's Laboratories Ltd. (RDY) said that it has launched Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma.

therapy in combination with radiotherapy is an effective treatment for late-stage nasopharyngeal carcinoma (NPC). The authors conclude that radiotherapy combined with intratumoral administration ...

Dr Reddy’s Laboratories launches Toripalimab, the first immuno-oncology drug for nasopharyngeal carcinoma, in India. Toripalimab, a PD-1 inhibitor, provides a new treatment option for this rare ...

Chen, QY., Chen, D. et al. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. Nat Med 27, 1536–1543 ...

Dr. Reddy's entered into a licensing and commercialization agreement with Shanghai Junshi Biosciences for toripalimab.

“The launch of Toripalimab is a significant milestone for patients diagnosed with nasopharyngeal carcinoma (NPC) in India. NPC is a rare form of head and neck cancer. However, the prognosis of ...

M.V. Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), Dr. Reddy’s, said: "The launch of Toripalimab is a significant milestone for patients diagnosed with nasopharyngeal ...